Free tool
FAERS Monitor: Atropine Sulfate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021146 or its brand name (Atropine Sulfate, Atropine Sulfate). Reports on generic versions are filed under their own applications.
Reports
2,540
Serious
2,136
84% of reports
Hospitalization
969
Death reported
398
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective315
- off label use211
- macular degeneration199
- nausea193
- pyrexia161
- diarrhoea149
- pain136
- malaise132
- headache129
- weight decreased120
- death118
- constipation115
- erythema109
- vomiting105
- abdominal pain103
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 55 |
| 2005 | 62 |
| 2006 | 50 |
| 2007 | 55 |
| 2008 | 72 |
| 2009 | 45 |
| 2010 | 75 |
| 2011 | 67 |
| 2012 | 71 |
| 2013 | 60 |
| 2014 | 67 |
| 2015 | 74 |
| 2016 | 112 |
| 2017 | 90 |
| 2018 | 122 |
| 2019 | 181 |
| 2020 | 158 |
| 2021 | 146 |
| 2022 | 226 |
| 2023 | 231 |
| 2024 | 232 |
| 2025 | 185 |
| 2026 | 103 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,619 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 199 | 140.3 | 122.6 | 26,940 |
| erythemaSignal | 109 | 4.4 | 3.7 | 285 |
| constipationSignal | 115 | 4.4 | 3.7 | 298 |
| pyrexiaSignal | 161 | 3.9 | 3.3 | 343 |
| abdominal painSignal | 103 | 3.7 | 3.0 | 199 |
| weight decreasedSignal | 120 | 3.6 | 3.0 | 221 |
| malaiseSignal | 132 | 2.5 | 2.1 | 119 |
| nauseaSignal | 193 | 2.0 | 1.8 | 102 |
| off label use | 211 | 2.0 | 1.8 | 108 |
| drug ineffective | 315 | 2.0 | 1.8 | 162 |
| diarrhoea | 149 | 1.9 | 1.6 | 66 |
| vomiting | 105 | 1.8 | 1.5 | 41 |
| pain | 136 | 1.8 | 1.6 | 52 |
| headache | 129 | 1.7 | 1.4 | 38 |
| death | 118 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.